Founded in 2006, MedDEV, Inc. focuses research and program development on new applications and formulations of older medicines, and the development of new, small molecule biomed programs — particularly for patient bases comprising depression, autism, Alzheimer’s, multiple sclerosis and bi-polar disorder.
Additional programs are in the design/research phase. Three therapies are in line for commencement of pre-clinical studies or expedited 505(b)(2) regulatory approval.
» AM4 — patent issued in the U.S. and Europe for use in multiple sclerosis, fibromyalgia, depression and memory impairment.
» EDL1 — patent issued in the U.S. for depression and depressive disorders. Patent pending in Europe.
» Respen-A™ — U.S. patent pending. Topical disc for treating symptoms of impaired communication, impaired social interaction, and disruptive repetitive behaviors.
Executive Management, Corporate Advisors and Scientific Advisory Board
MedDEV, Inc. Executive Management, Corporate Advisors and Scientific Advisory Board are comprised of successful, established leaders in the fields of business and medical research. Their combined mission is to create and produce cost-effective, advanced-formula therapeutics for those suffering from neurodegenerative and CNS-related disorders.
A privately-held company, MedDEV, Inc. was incorporated in the State of Washington in 2006.